Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2006-03-31

Study Completion Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the efficacy of Tacrolimus Treatment of patients with idiopathic focal segmental glomerulosclerosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis

NCT01451489

FSGS

TERMINATED NA

Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy

NCT00302523

Idiopathic Membranous Nephropathy

COMPLETED NA

Prospective, Multicenter Study of the Efficacy and Tolerance of Tacrolimus on Refractory Nephrotic Syndrome (RNS)

NCT00615667

Kidney Diseases Nephrotic Syndrome Tacrolimus

COMPLETED PHASE3

Prognostic Model of TAC in the Treatment of MN

NCT05667922

Idiopathic Membranous Nephropathy

UNKNOWN

Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome

NCT00362531

Idiopathic Membranous Nephropathy Nephrotic Syndrome

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary FSGS is a leading cause of end stage renal disease in adults, with complete loss of kidney function in 50% of patients over 10 years. Steroids, which are currently used to treat the disease, are effective in part of patients. Over the past decade, a number of studies have reported therapeutic efficacy for treatment with Cyclosporine-A (CSA) in patients with FSGS. Recent studies suggest that immunosuppressive therapy targeted against the calcineurin pathway of T-helper cells, for example, tacrolimus, may be effective in the treatment of primary FSGS. The experience with Tacrolimus (FK506) in the treatment of patients with FSGS has been limited to uncontrolled trials in adult patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Focal Glomerulosclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tacrolimus

Group Type EXPERIMENTAL

Tacrolimus

Intervention Type DRUG

Tacrolimus

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tacrolimus

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tacrolimus, Prograf

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 14-50 years at onset of signs or symptoms of FSGS
* Biopsy proven FSGS
* Estimated glomerular filtration rate (GFR) ≥ 40 ml/min/1.73 m2
* Urine protein \> 3.5 g/24h
* Biopsy confirmed primary FSGS (including all subtypes)
* Willingness to follow the clinical trial protocol, including medications, and baseline and follow-up visits and procedures

Exclusion Criteria

* Secondary FSGS
* Prior therapy with sirolimus, CSA, MMF, or azathioprin, cytoxan, chlorambucil levamisole, methotrexate, or nitrogen mustard in the last 90 days
* Active/serious infection
* Malignancy
* Previously diagnosed diabetes mellitus type 1 or 2
* Clinical evidence of cirrhosis or chronic active liver disease
* History of significant gastrointestinal disorder
* Allergy to study medications, and Inability to consent/assent

Minimum Eligible Age

15 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes